133 related articles for article (PubMed ID: 37828659)
21. All-trans retinoic acid (ATRA) regulates key genes in the RARG-TOP2B pathway and reduces anthracycline-induced cardiotoxicity.
Hasbullah JS; Scott EN; Bhavsar AP; Gunaretnam EP; Miao F; Soliman H; Carleton BC; Ross CJD
PLoS One; 2022; 17(11):e0276541. PubMed ID: 36331922
[TBL] [Abstract][Full Text] [Related]
22. Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the "European Paediatric Oncology Off-patents Medicines Consortium" (EPOC) Trial.
Hellmann F; Völler S; Krischke M; Jamieson D; André N; Bisogno G; Boddy A; Hempel G
Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):413-422. PubMed ID: 31981210
[TBL] [Abstract][Full Text] [Related]
23. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.
Aminkeng F; Bhavsar AP; Visscher H; Rassekh SR; Li Y; Lee JW; Brunham LR; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Amstutz U; Rieder MJ; Bernstein D; Carleton BC; Hayden MR; Ross CJ;
Nat Genet; 2015 Sep; 47(9):1079-84. PubMed ID: 26237429
[TBL] [Abstract][Full Text] [Related]
24. Association of genetic polymorphisms NCF4 rs1883112, CBR3 rs1056892, and ABCC1 rs3743527 with the cardiotoxic effects of doxorubicin in children with acute lymphoblastic leukemia.
Gándara-Mireles JA; Lares-Asseff I; Reyes Espinoza EA; Blanco JG; González Font AE; Córdova Hurtado LP; Castañeda VL; Fierro IV; Romero LP; Reyes HA
Pharmacogenet Genomics; 2021 Jul; 31(5):108-115. PubMed ID: 34096893
[TBL] [Abstract][Full Text] [Related]
25. SLC28A3 rs7853758 as a new biomarker of tacrolimus elimination and new-onset hypertension in Chinese liver transplantation patients.
Liu Y; Zhang T; Li C; Ye L; Gu H; Zhong L; Sun H; Sun Y; Peng Z; Fan J
Biomark Med; 2017 Aug; 11(8):607-618. PubMed ID: 28621555
[TBL] [Abstract][Full Text] [Related]
26. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.
Krajinovic M; Elbared J; Drouin S; Bertout L; Rezgui A; Ansari M; Raboisson MJ; Lipshultz SE; Silverman LB; Sallan SE; Neuberg DS; Kutok JL; Laverdière C; Sinnett D; Andelfinger G
Pharmacogenomics J; 2016 Nov; 16(6):530-535. PubMed ID: 26345518
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for anthracycline-associated cardiotoxicity.
Reinbolt RE; Patel R; Pan X; Timmers CD; Pilarski R; Shapiro CL; Lustberg MB
Support Care Cancer; 2016 May; 24(5):2173-2180. PubMed ID: 26563179
[TBL] [Abstract][Full Text] [Related]
28. Screening for
Chakouri N; Farah C; Matecki S; Amedro P; Vincenti M; Saumet L; Vergely L; Sirvent N; Lacampagne A; Cazorla O
Theranostics; 2020; 10(18):8130-8142. PubMed ID: 32724462
[TBL] [Abstract][Full Text] [Related]
29. Association between genetic variants of transmembrane transporters and susceptibility to anthracycline-induced cardiotoxicity: Current understanding and existing evidence.
Ni MM; Yang JF; Miao J; Xu J
Clin Genet; 2024 Feb; 105(2):115-129. PubMed ID: 37961936
[TBL] [Abstract][Full Text] [Related]
30. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children.
Visscher H; Rassekh SR; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Rogers PC; Rieder MJ; Carleton BC; Hayden MR; Ross CJ;
Pharmacogenomics; 2015; 16(10):1065-76. PubMed ID: 26230641
[TBL] [Abstract][Full Text] [Related]
31. NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors.
Zidan A; Sherief LM; El-sheikh A; Saleh SH; Shahbah DA; Kamal NM; Sherbiny HS; Ahmad H
Dis Markers; 2015; 2015():513219. PubMed ID: 25960594
[TBL] [Abstract][Full Text] [Related]
32. The Role of Metoprolol and Enalapril in the Prevention of Doxorubicin-induced Cardiotoxicity in Lymphoma Patients.
Georgakopoulos P; Kyriakidis M; Perpinia A; Karavidas A; Zimeras S; Mamalis N; Kouvela M; Charpidou A
Anticancer Res; 2019 Oct; 39(10):5703-5707. PubMed ID: 31570470
[TBL] [Abstract][Full Text] [Related]
33. Unexpected doxorubicin-mediated cardiotoxicity in sisters: possible role of polymorphisms in histamine n-methyl transferase.
Sachidanandam K; Gayle AA; Robins HI; Kolesar JM
J Oncol Pharm Pract; 2013 Sep; 19(3):269-72. PubMed ID: 23154571
[TBL] [Abstract][Full Text] [Related]
34. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
35. Impact of single-nucleotide variants and nutritional status on population pharmacokinetics of Doxorubicin, and its effect on cardiotoxicity in children with leukemia.
Gándara-Mireles JA; Lares-Asseff I; Reyes Espinoza EA; Fierro IV; Castañeda VL; Cordova Hurtado LP; González CD; Romero LP; Reyes HA
J Oncol Pharm Pract; 2023 Sep; 29(6):1290-1305. PubMed ID: 36113156
[TBL] [Abstract][Full Text] [Related]
36. Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.
Çetin S; Babaoğlu K; Başar EZ; Deveci M; Çorapçıoğlu F
Echocardiography; 2018 Feb; 35(2):234-240. PubMed ID: 29106752
[TBL] [Abstract][Full Text] [Related]
37. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
de Baat EC; van Dalen EC; Mulder RL; Hudson MM; Ehrhardt MJ; Engels FK; Feijen EAM; Grotenhuis HB; Leerink JM; Kapusta L; Kaspers GJL; Merkx R; Mertens L; Skinner R; Tissing WJE; de Vathaire F; Nathan PC; Kremer LCM; Mavinkurve-Groothuis AMC; Armenian S
Lancet Child Adolesc Health; 2022 Dec; 6(12):885-894. PubMed ID: 36174614
[TBL] [Abstract][Full Text] [Related]
38. Telomerase therapy attenuates cardiotoxic effects of doxorubicin.
Chatterjee S; Hofer T; Costa A; Lu D; Batkai S; Gupta SK; Bolesani E; Zweigerdt R; Megias D; Streckfuss-Bömeke K; Brandenberger C; Thum T; Bär C
Mol Ther; 2021 Apr; 29(4):1395-1410. PubMed ID: 33388418
[TBL] [Abstract][Full Text] [Related]
39. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
40. Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients.
Ruggeri C; Gioffré S; Achilli F; Colombo GI; D'Alessandra Y
Heart Fail Rev; 2018 Jan; 23(1):109-122. PubMed ID: 28944400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
